Three details:
- Under the agreement, St. Jude will provide the artificial intelligence company access to pediatric imaging datasets for use in the development of its patented AI technology, called IB Zero G, according to a Nov. 11 news release.
- IB Zero G will be used to generate synthetic contrast-enhanced images for pediatric neuro examinations as an alternative to using contrast agents in patients, according to the release.
- “This agreement will accelerate the development and commercialization of IB Zero G,” said Trevor Brown, CEO of IQ-AI. “Avoiding the use of gadolinium-based contrast agents while preserving the diagnostic quality on pediatric images will help clinicians address concerns relating to GBCA retention and ultimately provide better care.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.